{{Distinguish|Doxepin}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 448788673
| IUPAC_name = (3''E'')-3-(6''H''-benzo[''c''][1]benzothiepin-11-ylidene)-''N'',''N''-dimethylpropan-1-amine
| image = Dosulepin2DACS2.svg
| width = 200px
| image2 = Dosulepin-from-HCl-1987-xtal-CCDC-1160822.png
| width2 = 225px
| USAN = dothiepin

<!--Clinical data-->
| tradename = Prothiaden, others
| Drugs.com = {{drugs.com|international|dosulepin}}
| pregnancy_AU = C
| legal_AU = S4
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 30%<ref name="pmid2670509" />
| protein_bound = 84%<ref name="TGA" />
| metabolism = [[Liver|Hepatic]] (N-[[demethylation]], S-[[oxidation]], [[glucuronidation]])<ref name="TGA" />
| metabolites = Northiaden, dothiepin sulfoxide, northiaden sulfoxide, [[glucuronide]] [[conjugation (biochemistry)|conjugate]]s<ref name="pmid2670509" />
| elimination_half-life = Dothiepin: 14.4–23.9 hours<ref name="pmid2670509" /><br />Dothiepin sulfoxide: 22.7–25.5 hours<ref name="pmid2670509" /><br />Northiaden: 34.7–45.7 hours<ref name="pmid2670509" /><br />Northiaden sulfoxide: 24.2–33.5 hours<ref name="pmid2670509" />
| excretion = [[Urine]]: 56%<ref name="pmid2670509" /><br />[[Feces]]: 15%<ref name="pmid2670509" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 25627-37-6
| CAS_supplemental = <br />^ (''E'' isomer)<ref name="Elks2014" /><br />25627-36-5 (''E'' isomer {{abbrlink|HCl|hydrochloride}})<ref name="ChemIDplus-3" /><br />113-53-1 ([[racemate]])<ref name="ChemIDplus-1" /><ref name="Elks2014" /><ref name="IndexNominum2000" /><br />897-15-4 (racemate {{abbr|HCl|hydrochloride}})<ref name="ChemIDplus-2" />
| ATC_prefix = N06
| ATC_suffix = AA16
| PubChem = 5284550
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W13O82Z7HL
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07872
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 36803
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 108947
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4447605
| synonyms = IZ-914, KS-1596<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="Drugs.com" />

<!--Chemical data-->
| C=19 | H=21 | N=1 | S=1 
| molecular_weight = 295.444 g/mol
| SMILES = CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = PHTUQLWOUWZIMZ-GZTJUZNOSA-N
}}

'''Dosulepin''', also known as '''dothiepin''' and sold under the brand name '''Prothiaden''' among others, is a [[tricyclic antidepressant]] (TCA) which is used in the treatment of [[depression (mood)|depression]].<ref name="pmid2670509">{{cite journal | vauthors = Lancaster SG, Gonzalez JP | title = Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness | journal = Drugs | volume = 38 | issue = 1 | pages = 123–47 | year = 1989 | pmid = 2670509 | doi = 10.2165/00003495-198938010-00005 | url = }}</ref><ref name="pmid7846285">{{cite journal | vauthors = Donovan S, Dearden L, Richardson L | title = The tolerability of dothiepin: a review of clinical studies between 1963 and 1990 in over 13,000 depressed patients | journal = Prog. Neuropsychopharmacol. Biol. Psychiatry | volume = 18 | issue = 7 | pages = 1143–62 | year = 1994 | pmid = 7846285 | doi = | url = }}</ref><ref name="MD"/> Dosulepin was once the most frequently prescribed antidepressant in the [[United Kingdom]], but it is no longer widely used due to its relatively high [[toxicity]] in [[overdose]] without therapeutic advantages over other TCAs.<ref name="pmid7846285"/><ref name="pmid16390222">{{cite journal | vauthors = Thanacoody HK, Thomas SH | title = Tricyclic antidepressant poisoning : cardiovascular toxicity | journal = Toxicol Rev | volume = 24 | issue = 3 | pages = 205–14 | year = 2005 | pmid = 16390222 | doi = | url = }}</ref><ref name="pmid17471183">{{cite journal | vauthors = Gillman PK | title = Tricyclic antidepressant pharmacology and therapeutic drug interactions updated | journal = Br. J. Pharmacol. | volume = 151 | issue = 6 | pages = 737–48 | year = 2007 | pmid = 17471183 | pmc = 2014120 | doi = 10.1038/sj.bjp.0707253 | url = }}</ref> It acts as a [[serotonin–norepinephrine reuptake inhibitor]] (SNRI) and also has other activities including [[antihistamine]], [[antiadrenergic]], [[antiserotonergic]], [[anticholinergic]], and [[sodium channel blocker|sodium channel-blocking]] effects.<ref name="pmid2670509" /><ref name="LemkeWilliams2012" /><ref name="HealCheetham1992" />

==Medical uses==
Dosulepin is used for the treatment of [[major depressive disorder]].<ref name="pmid2670509" /><ref name="TGA">{{cite web|title=Dothep Dothiepin hydrochloride|work=TGA eBusiness Services|publisher=Alphapharm Pty Limited|date=1 November 2013|accessdate=3 December 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04551-3|format=PDF}}</ref><ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref><ref name="BNF">{{cite book | isbn = 978-0-85711-084-8 | title = British National Formulary (BNF) | last1 = Joint Formulary Committee | year = 2013 | publisher = Pharmaceutical Press | location = London, UK | edition = 65 | pages = }}</ref> There is clear evidence of the efficacy of dosulepin in [[atypical facial pain|psychogenic facial pain]], though the drug may be needed for up to a year.<ref>{{cite journal |title= Psychogenic facial pain: presentation and treatment. |author1=C Feinmann |author2=M Harris |author3=R Cawley |date= 11 February 1984 |pmc=1444752 |pmid=6419955 |volume=288 |pages=436–8 |journal=Br Med J (Clin Res Ed) |doi=10.1136/bmj.288.6415.436}}</ref>

==Contraindications==
Contraindications include:<ref name="TGA" />

* [[Epilepsy]] as it can lower the seizure threshold
* TCAs should not be used concomitantly or within 14 days of treatment with monoamine oxidase inhibitors due to the risk for [[serotonin syndrome]]
* Acute recovery phase following [[myocardial infarction]] as TCAs may produce conduction defects and arrhythmias
* [[Liver failure]]
* Hypersensitivity to dosulepin

==Side effects==
'''Common adverse effects:'''<ref name="TGA" />

{{colbegin|4}}
* Drowsiness
* [[Extrapyramidal symptoms]]
* Tremor
* Confusion
* Disorientation
* Dizziness
* [[Paresthesia]]s
* Alterations to [[Electrocardiogram|ECG]] patterns
* Dry mouth
* Sweating
* [[Urinary retention]]
* Hypotension
* Postural hypotension
* Tachycardia
* Palpitations
* Arrhythmias
* Conduction defects
* Increased or decreased libido
* Nausea
* Vomiting
* Constipation
* Blurred vision
{{colend}}

'''Less common adverse effects:'''<ref name="TGA" />
{{colbegin|3}}
* Disturbed concentration
* [[Delusions]]
* [[Hallucinations]]
* Anxiety
* Fatigue
* Headaches
* Restlessness
* Excitement
* Insomnia
* [[Hypomania]]
* Nightmares
* [[Peripheral neuropathy]]
* [[Ataxia]]
* Incoordination
* Seizures
* Paralytic [[ileus]]
* Hypertension
* Heart block
* [[Myocardial infarction]]
* Stroke
* [[Gynecomastia]] (swelling of breast tissue in males)
* Testicular swelling
* Impotence
* Epigastric distress
* Abdominal cramps
* Parotid swellings
* Diarrhea
* [[Stomatitis]] (swelling of the mouth)
* Black tongue
* Peculiar taste sensations
* Cholestatic [[jaundice]]
* Altered liver function
* [[Hepatitis]] (swelling of the liver)
* Skin rash
* Urticaria (hives)
* Photosensitisation
* Skin blisters
* Angioneurotic edema
* Weight loss
* Urinary frequency
* Mydriasis
* Weight gain
* [[Hyponatremia]] (low blood sodium)
* Movement disorders
* [[Dyspepsia]] (indigestion)
* Increased intraocular pressure
* Changes in blood sugar levels
{{colend}}
* [[Thrombocytopenia]] (an abnormally low number of [[platelets]] in the blood. This makes one more susceptible to bleeds)
* [[Eosinophilia]] (an abnormally high amount of eosinophils in the blood) 
* [[Agranulocytosis]] (a dangerously low number of white blood cells in the blood leaving one open to potentially life-threatening infections)
* [[Galactorrhea]] (lactation that is unassociated with breastfeeding and lactation)

==Overdose==
{{Main|Tricyclic antidepressant overdose}}

The symptoms and the treatment of an overdose are largely the same as for the other TCAs.<ref name = AMH/> Dosulepin may be particularly toxic in overdose compared to other TCAs.<ref name = AMH/> The onset of toxic effects is around 4–6 hours after dosulepin is ingested.<ref name="TGA" /> In order to minimise the risk of overdose it is advised that patients only receive a limited number of tablets at a time so as to limit their risk of overdosing.<ref name="TGA" /> It is also advised that patients are not prescribed any medications that are known to increase the risk of toxicity in those receiving dosulepin due to the potential for mixed overdoses.<ref name="TGA" /> The medication should also be kept out of reach of children.<ref name="TGA" />

==Interactions==
Dosulepin can potentiate the effects of alcohol and at least one death has been attributed to this combination.<ref name="TGA" /> TCAs potentiate the sedative effects of barbiturates, tranquilizers and {{abbrlink|CNS|central nervous system}} [[depressant]]s.<ref name="TGA" /> [[Guanethidine]] and other adrenergic neuron blocking drugs can have their antihypertensive effects blocked by dosulepin.<ref name="TGA" /> Sympathomimetics may potentiate the sympathomimetic effects of dosulepin.<ref name="TGA" /> Due to the anticholinergic and antihistamine effects of dosulepin anticholinergic and antihistamine medications may have their effects potentiated by dosulepin and hence these combinations are advised against.<ref name="TGA" /> Dosulepin may have its postural hypotensive effects potentiated by [[diuretics]].<ref name="TGA" /> Anticonvulsants may have their efficacy reduced by dosulepin due to its ability to reduce the seizure threshold.<ref name="TGA" />

==Pharmacology==

===Pharmacodynamics===
{{See also|Pharmacology of antidepressants|Tricyclic antidepressant#Binding profiles}}
{| class="wikitable floatright" style="font-size:small;"
|+ Dosulepin (and metabolite)<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=dothiepin&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! {{abbr|DSP|Dosulepin}} !! {{abbrlink|NTD|Northiaden}} !! Species !! Ref
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''8.6–78''' || '''192''' || '''Human/rat''' || <ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2-3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = | url = }}</ref><ref name="HealCheetham1992">{{cite journal|last1=Heal|first1=David|last2=Cheetham|first2=Sharon|last3=Martin|first3=Keith|last4=Browning|first4=John|last5=Luscombe|first5=Graham|last6=Buckett|first6=Roger|title=Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs|journal=Drug Development Research|volume=27|issue=2|year=1992|pages=121–135|issn=0272-4391|doi=10.1002/ddr.430270205}}</ref>
|-
| '''{{abbrlink|NET|Norepinephrine transporter}}''' || '''46–70''' || '''25''' || '''Human/rat''' || <ref name="pmid9537821" /><ref name="HealCheetham1992" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || 5,310 || 2,539 || Human/rat || <ref name="pmid9537821" /><ref name="HealCheetham1992" />
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 4,004 || 2,623 || Rat || <ref name="pmid10379421">{{cite journal |vauthors=Sánchez C, Hyttel J |title=Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding |journal=Cell. Mol. Neurobiol. |volume=19 |issue=4 |pages=467–89 |year=1999 |pmid=10379421 |doi= |url=}}</ref>
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''152''' || '''141''' || '''Rat''' || <ref name="HealCheetham1992" />
|-
| [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] || 419 || 950 || Rat || <ref name="HealCheetham1992" />
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || 2,400 || {{abbr|ND|No data}} || Human || <ref name="pmid6086881">{{cite journal | vauthors = Richelson E, Nelson A | title = Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro | journal = J. Pharmacol. Exp. Ther. | volume = 230 | issue = 1 | pages = 94–102 | year = 1984 | pmid = 6086881 | doi = | url = }}</ref>
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || '''3.6–4''' || '''25''' || '''Human/rat''' || <ref name="HealCheetham1992" /><ref name="pmid6086881" />
|-
| '''{{abbrlink|mACh|Muscarinic acetylcholine receptor}}''' || '''25–26''' || '''110''' || '''Human/rat''' || <ref name="HealCheetham1992" /><ref name="pmid7855217">{{cite journal | vauthors = Cusack B, Nelson A, Richelson E | title = Binding of antidepressants to human brain receptors: focus on newer generation compounds | journal = Psychopharmacology | volume = 114 | issue = 4 | pages = 559–65 | year = 1994 | pmid = 7855217 | doi = | url = }}</ref>
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]]''' || '''18''' || '''{{abbr|ND|No data}}''' || '''Human''' || <ref name="pmid8100134">{{cite journal |vauthors=Stanton T, Bolden-Watson C, Cusack B, Richelson E |title=Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics |journal=Biochem. Pharmacol. |volume=45 |issue=11 |pages=2352–4 |year=1993 |pmid=8100134 |doi= |url=}}</ref>
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]]''' || '''109''' || '''{{abbr|ND|No data}}''' || '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]]''' || '''38''' || '''{{abbr|ND|No data}}''' || '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]]''' || '''61''' || '''{{abbr|ND|No data}}''' ||  '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]]''' || '''92''' || '''{{abbr|ND|No data}}''' || '''Human''' || <ref name="pmid8100134" />
|- class="sortbottom"
| colspan="5" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

Dosulepin is a [[transporter blocker]] of the [[serotonin transporter]] (SERT) and the [[norepinephrine transporter]] (NET), thereby acting as an SNRI.<ref name="HealCheetham1992" /><ref name="LemkeWilliams2012" /> It is also an [[receptor antagonist|antagonist]] of the [[histamine]] [[H1 receptor|H<sub>1</sub> receptor]], [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]], [[serotonin]] [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s, and [[muscarinic acetylcholine receptor]]s (mACh), as well as a [[sodium channel blocker|blocker]] of [[voltage-gated sodium channel]]s (VGSCs).<ref name="HealCheetham1992" /><ref name="pmid2670509" /> The antidepressant effects of dosulepin are thought to be due to [[reuptake inhibitor|inhibition]] of the [[reuptake]] of [[norepinephrine]] and possibly also of serotonin.<ref name="pmid2670509" />

Dosulepin has three [[metabolites]], northiaden (desmethyldosulepin), dosulepin sulfoxide, and northiaden sulfoxide, which have longer [[terminal half-life|terminal half-lives]] than that of dosulepin itself.<ref name="HealCheetham1992" /> However, whereas northiaden has potent activity similarly to dosulepin, the two sulfoxide metabolites have dramatically reduced activity.<ref name="HealCheetham1992" /> They have been described as essentially inactive, and are considered unlikely to contribute to either the therapeutic effects or side effects of dosulepin.<ref name="HealCheetham1992" /> Relative to dosulepin, northiaden has reduced activity as a [[serotonin reuptake inhibitor]], [[antihistamine]], and [[anticholinergic]] and greater potency as a [[norepinephrine reuptake inhibitor]],<ref name="HealCheetham1992" /> similarly to other [[secondary amine]] TCAs.<ref name="HalesYudofsky2011">{{cite book|author1=Robert E. Hales|author2=Stuart C. Yudofsky|author3=Glen O. Gabbard|title=Essentials of Psychiatry|url=https://books.google.com/books?id=Hf50vMMMv_wC&pg=PA468|year=2011|publisher=American Psychiatric Pub|isbn=978-1-58562-933-6|pages=468–}}</ref><ref name="BurtisAshwood2012">{{cite book|author1=Carl A. Burtis|author2=Edward R. Ashwood|author3=David E. Bruns|title=Tietz Textbook of Clinical Chemistry and Molecular Diagnostics - E-Book|url=https://books.google.com/books?id=BBLRUI4aHhkC&pg=PA1129|date=14 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-5942-2|pages=1129–}}</ref> Unlike the sulfoxide metabolites, northiaden is thought to play an important role in the effects of dosulepin.<ref name="HealCheetham1992" />

Although Heal & Cheetham (1992) reported relatively high K<sub>i</sub> values of 12 and 15&nbsp;nM for dosulepin and northiaden at the rat α<sub>2</sub>-adrenergic receptor and suggested that antagonism of the receptor could be involved in the antidepressant effects of dosulepin,<ref name="HealCheetham1992" /> Richelson & Nelson (1984) found a low K<sub>D</sub> of only 2,400&nbsp;nM for dosulepin at this receptor using human brain tissue.<ref name="pmid6086881" /> This suggests that it in fact has low potency for this action, similarly to other TCAs.<ref name="pmid6086881" />

===Pharmacokinetics===
Dosulepin is readily absorbed from the small intestine and is extensively metabolized on first-pass through the liver into its chief active metabolite, northiaden.<ref name="TGA" /> Peak plasma concentrations of between 30.4 to 279&nbsp;ng/mL (103–944&nbsp;nmol/L) occur within 2–3 hours of oral administration.<ref name="TGA" /> It is distributed in breast milk and crosses the placenta and [[blood-brain barrier]].<ref name="TGA" /> It is highly bound to plasma proteins (84%), and has a whole-body [[elimination half-life]] of 51&nbsp;hours.<ref name="TGA" />

==Chemistry==
Dosulepin is a [[tricyclic compound]], specifically a [[dibenzothiepine]], and possesses three [[ring (chemistry)|ring]]s fused together with a [[side chain]] attached in its [[chemical structure]].<ref name="Aronson2009">{{cite book|author=J. K. Aronson|title=Meyler's Side Effects of Psychiatric Drugs|url=https://books.google.com/books?id=AmYFTSO8jCkC&pg=PA7|year=2009|publisher=Elsevier|isbn=978-0-444-53266-4|pages=7–}}</ref> It is the only TCA with a dibenzothiepine [[ring system (chemistry)|ring system]] to have been marketed.<ref name="Aronson2009" /><ref name="Ritsner2013">{{cite book|author=Michael S Ritsner|title=Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies|url=https://books.google.com/books?id=jy-LMZU7338C&pg=PA270|date=15 February 2013|publisher=Springer Science & Business Media|isbn=978-94-007-5805-6|pages=270–271}}</ref> The drug is a [[tertiary amine]] TCA, with its [[side chain]]-[[demethylation|demethylated]] metabolite northiaden (desmethyldosulepin) being a [[secondary amine]].<ref name="CutlerSramek1994">{{cite book|author1=Neal R. Cutler|author2=John J. Sramek|author3=Prem K. Narang|title=Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology|url=https://books.google.com/books?id=ncRXa8Dq88QC&pg=PA160|date=20 September 1994|publisher=John Wiley & Sons|isbn=978-0-471-95052-3|pages=160–}}</ref><ref name="AnzenbacherZanger2012">{{cite book|author1=Pavel Anzenbacher|author2=Ulrich M. Zanger|title=Metabolism of Drugs and Other Xenobiotics|url=https://books.google.com/books?id=f-XHh17NfwgC&pg=PA302|date=23 February 2012|publisher=John Wiley & Sons|isbn=978-3-527-64632-6|pages=302–}}</ref> Other tertiary amine TCAs include [[amitriptyline]], [[imipramine]], [[clomipramine]], [[doxepin]], and [[trimipramine]].<ref name="Anthony2002">{{cite book|author=Patricia K. Anthony|title=Pharmacology Secrets|url=https://books.google.com/books?id=_QQsj3PAUrEC&pg=PA39|year=2002|publisher=Elsevier Health Sciences|isbn=1-56053-470-2|pages=39–}}</ref><ref name="CowenHarrison2012">{{cite book|author1=Philip Cowen|author2=Paul Harrison|author3=Tom Burns|title=Shorter Oxford Textbook of Psychiatry|url=https://books.google.com/books?id=Y1DtSGq-LnoC&pg=PA532|date=9 August 2012|publisher=OUP Oxford|isbn=978-0-19-162675-3|pages=532–}}</ref> Dosulepin exhibits [[Stereoisomerism#Cis–trans and E-Z isomerism|(''E'') and (''Z'')]] [[stereoisomerism]] like [[doxepin]] but in contrast is used as the pure ''E'' or ''trans'' isomer.<ref name="Elks2014" /><ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA607|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=607–}}</ref><ref name="Springer2012">{{cite book|title=Psychotropic Agents: Part I: Antipsychotics and Antidepressants|url=https://books.google.com/books?id=oK7tCAAAQBAJ&pg=PA354|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-67538-6|pages=354–}}</ref> The [[chemical name]] of dosulepin is (''E'')-3-(dibenzo[''b'',''e'']thiepin-11(6''H'')-ylidene)-''N'',''N''-dimethylpropan-1-amine and its [[free base]] form has a [[chemical formula]] of C<sub>19</sub>H<sub>21</sub>NS with a [[molecular weight]] of 295.444&nbsp;g/mol.<ref name="Elks2014" /> The drug is used commercially as the [[hydrochloride]] [[salt (chemistry)|salt]]; the free base is not used.<ref name="Elks2014" /><ref name="IndexNominum2000" /> The [[CAS Registry Number]] of the racemate is 113-53-1,<ref name="ChemIDplus-1">https://chem.nlm.nih.gov/chemidplus/rn/113-53-1</ref><ref name="Elks2014" /><ref name="IndexNominum2000" /> of the racemate hydrochloride is 897-15-4,<ref name="ChemIDplus-2">https://chem.nlm.nih.gov/chemidplus/rn/897-15-4</ref> of the ''E'' isomer is 25627-37-6,<ref name="Elks2014" /> and of the ''E'' isomer hydrochloride is 25627-36-5.<ref name="ChemIDplus-3">https://chem.nlm.nih.gov/chemidplus/rn/25627-36-5</ref>

==History==
Dosulepin was developed by SPOFA.<ref name="pmid19557250">{{cite journal | vauthors = Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K | title = Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters | journal = Chem. Commun. (Camb.) | volume = | issue = 25 | pages = 3677–92 | year = 2009 | pmid = 19557250 | doi = 10.1039/b903035m | url = }}</ref> It was patented in 1962 and first appeared in the literature in 1962.<ref name="pmid19557250" /> The drug was first introduced for medical use in 1969, in the [[United Kingdom]].<ref name="pmid19557250" /><ref name="Dart2004">{{cite book|author=Richard C. Dart|title=Medical Toxicology|url=https://books.google.com/books?id=BfdighlyGiwC&pg=PA836|year=2004|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-2845-4|pages=836–}}</ref>

==Society and culture==

===Generic names===
''Dosulepin'' is the [[English language|English]] and [[German language|German]] [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}} and {{abbrlink|BAN|British Approved Name}}, while ''dosulepin hydrochloride'' is its {{abbrlink|BANM|British Approved Name}} and {{abbrlink|JAN|Japanese Accepted Name}}.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA468|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=468–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA369|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=369–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA105|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=105–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/dosulepin.html</ref> ''Dothiepin'' is the former {{abbrlink|BAN|British Approved Name}} of the drug while ''dothiepin hydrochloride'' is the former {{abbrlink|BANM|British Approved Name}} and remains the current {{abbrlink|USAN|United States Adopted Name}}.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="MortonHall2012" /><ref name="Drugs.com" /> Its generic name in [[Spanish language|Spanish]] and [[Italian language|Italian]] and its {{abbrlink|DCIT|Denominazione Comune Italiana}} are ''dosulepina'', in [[French language|French]] and its {{abbrlink|DCF|Dénomination Commune Française}} are ''dosulépine'', and in [[Latin language|Latin]] is ''dosulepinum''.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

===Brand names===
Dosulepin is marketed throughout the world mainly under the brand name Prothiaden.<ref name="IndexNominum2000" /><ref name="Drugs.com" /> It is or has been marketed under a variety of other brand names as well, including Altapin, Depresym, Dopress, Dothapax, Dothep, Idom, Prepadine, Protiaden, Protiadene, Thaden, and Xerenal.<ref name="Elks2014" /><ref name="MortonHall2012" /><ref name="IndexNominum2000" /><ref name="Drugs.com" />

===Availability===
Dosulepin is marketed throughout [[Europe]] (as Prothiaden, Protiaden, and Protiadene), [[Australia]] (as Dothep and Prothiaden), [[New Zealand]] (as Dopress) and [[South Africa]] (as Thaden).<ref name="IndexNominum2000" /><ref name="Drugs.com" /><ref name="MD">{{cite book|title=Dosulepin Hydrochloride|work=Martindale: The Complete Drug Reference|date=5 December 2011|accessdate=15 August 2017|url=http://www.medicinescomplete.com/mc/martindale/current/2512-p.htm|publisher=Pharmaceutical Press|location=London, UK}}</ref><ref name="AMH"/><ref name="BNF"/> It is also available in [[Japan]], [[Hong Kong]], [[Taiwan]], [[India]], [[Singapore]], and [[Malaysia]].<ref name="IndexNominum2000" /><ref name="Drugs.com" /><ref name="MD" /> The drug is not available in the [[United States]] or [[Canada]].<ref name="IndexNominum2000" /><ref name="Drugs.com" /><ref name="MD" />

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Neuropathic pain and fibromyalgia pharmacotherapies}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Histamine receptor modulators}}
{{Ion channel modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Alpha-1 blockers]]
[[Category:Amines]]
[[Category:Analgesics]]
[[Category:Antihistamines]]
[[Category:Dibenzothiepines]]
[[Category:Muscarinic antagonists]]
[[Category:Serotonin antagonists]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]
[[Category:Sodium channel blockers]]
[[Category:Tricyclic antidepressants]]